Psychiatry & Neurology Doctors in Prescott Valley, AZ Accepting Medicare

7 Psychiatry & Neurology doctors found. Showing 1 - 7

Barry Coe, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 3345 N Windsong Dr, Prescott Valley, AZ 86314 Phone: 928-445-5211

Dr. Lisa Marie Parsons, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 3345 N Windsong Dr, Prescott Valley, AZ 86314 Phone: 602-228-9503

Mark Jerome Collins, DO Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Medicare Enrolled Practice Location: 5940 E Copper Hill Dr, Suite B, Prescott Valley, AZ 86314 Phone: 702-379-2227

Dr. David Sidney Burgoyne Ii, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 8011 N Racehorse Rd, Prescott Valley, AZ 86315 Phone: 480-980-8540

Stacey Sabatina, NP Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 7750 E Florentine Rd Ste A, Prescott Valley, AZ 86314 Phone: 928-277-1211    Fax: 928-277-1208

Raquel Balderas, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 3345 N Windsong Dr, Windsong Center, Prescott Valley, AZ 86314 Phone: 928-445-5211    Fax: 928-776-8484

Gayle L Gregory, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 15801 E Don Carlos Dr, Prescott Valley, AZ 86315 Phone: 602-335-2000    Fax: 602-476-2077

News Archive

Antibe Therapeutics closes previously announced non-brokered private placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") has closed its previously announced non-brokered private placement raising gross proceeds of $3,015,398 (the "Offering") on the sale of 5,025,664 Common Shares of the Corporation.

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat population and 85% in the per-protocol population, a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care.

UBC researcher finds improved uptake of highly active antiretroviral therapy

A comprehensive population-based study, conducted by the BC Centre for Excellence in HIV/AIDS (BC-CfE) and presented at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco, shows that expanded highly active antiretroviral therapy (HAART) coverage was associated with a 50% decrease in new yearly HIV infections among injection drug users.

Breakthrough in development of effective therapy against Hendra virus

A team of Federal and university scientists reports a breakthrough in the development of an effective therapy against a deadly virus, Hendra virus. The results of their study, "A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge," will appear in Science Translational Medicine online.

Graphene can purify water, making it drinkable without further chlorination

Scientists from the National University of Science and Technology "MISIS" together with their colleagues from Derzhavin Tambov State University and Saratov Chernyshevsky State University have figured out that graphene is capable of purifying water, making it drinkable, without further chlorination.

Read more Medical News

› Verified 7 days ago